Prognostic implications of EGFR and HER-2 alteration assessed by immunohistochemistry and silver in situ hybridization in gastric cancer patients following curative resection

Gastric Cancer

Volumn 17, Issue 3, 2014, Pages 402-411

  Oh, Ho Suk ^a   Eom, Dae Woon ^a   Kang, Gil Hyun ^a   Ahn, Yong Chel ^a   Lee, Sang Jin ^a   Kim, Ji Hoon ^a   Jang, Hyuk Jai ^a   Kim, Eun Jung ^a   Oh, Kwang Hoon ^a   Ahn, Heui June ^a  

^a University of Ulsan College of Medicine   (South Korea)

Author keywords

EGFR; Gastric cancer; HER 2; IHC; Prognosis; SISH

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; SILVER;

AGED; ARTICLE; CANCER GRADING; CANCER PROGNOSIS; CANCER STAGING; CLINICAL EVALUATION; CLINICAL FEATURE; DISEASE ASSOCIATION; EGFR GENE; FEMALE; FOLLOW UP; GASTRECTOMY; HER2 GENE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN DEFECT; PROTEIN EXPRESSION; RECURRENCE FREE SURVIVAL; SILVER IN SITU HYBRIDIZATION; STOMACH CANCER; TISSUE MICROARRAY; TUMOR DIFFERENTIATION; ADULT; AGE; METABOLISM; MIDDLE AGED; MULTIVARIATE ANALYSIS; PATHOLOGY; PROCEDURES; PROGNOSIS; STOMACH NEOPLASMS; VERY ELDERLY;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; PROGNOSIS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; SILVER; STOMACH NEOPLASMS;

EID: 84903709778     PISSN: 14363291     EISSN: 14363305     Source Type: Journal    
DOI: 10.1007/s10120-013-0288-0     Document Type: Article

References (47)

1. Matsubara J, Hirashima Y, Yamada Y. Impact of HER2, EGFR, IGF-1R, and VEGFR expressions on the outcome of chemotherapy for advanced gastric cancer. Gan To Kagaku Ryoho. 2010;37:1489-96.
2. Sano T. Tailoring treatments for curable gastric cancer. Br J Surg. 2007;94:263-4. (Pubitemid 46423841)
3. Roukos DH. Extended lymphadenectomy in gastric cancer: when, for whom and why. Ann R Coll Surg Engl. 1998;80:16-24. (Pubitemid 28043653)
4. Roukos DH, Kappas AM. Targeting the optimal extent of lymph node dissection for gastric cancer. J Surg Oncol. 2002;81:59-62 (discussion).
5. Siewert JR, Bottcher K, Stein HJ, Roder JD. Relevant prognostic factors in gastric cancer: ten-year results of the German Gastric Cancer Study. Ann Surg. 1998;228:449-61. (Pubitemid 30194389)
6. Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376:687-97.
7. Wang YK, Gao CF, Yun T, Chen Z, Zhang XW, Lv XX. Assessment of ERBB2 and EGFR gene amplification and protein expression in gastric carcinoma by immunohistochemistry and fluorescence in situ hybridization. Mol Cytogenet. 2011;4:14.
8. Ishikawa T, Kobayashi M, Mai M, Suzuki T, Ooi A. Amplification of the c-erbB-2 (HER-2/neu) gene in gastric cancer cells. Detection by fluorescence in situ hybridization. Am J Pathol. 1997;151:761-8. (Pubitemid 27385608)
9. Park DI, Yun JW, Park JH, Oh SJ, Kim HJ, Cho YK, et al. HER- 2/neu amplification is an independent prognostic factor in gastric cancer. Dig Dis Sci. 2006;51:1371-9. (Pubitemid 44315804)
10. Nitta H, Hauss-Wegrzyniak B, Lehrkamp M, Murillo AE, Gaire F, Farrell M, et al. Development of automated brightfield double in situ hybridization (BDISH) application for HER2 gene and chromosome 17 centromere (CEN 17) for breast carcinomas and an assay performance comparison to manual dual color HER2 fluorescence in situ hybridization (FISH). Diagn Pathol. 2008; 3:41.
11. Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol. 2007;25:118-45. (Pubitemid 350003059)
12. Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010; 376:687-97.
13. Shin HR, Jung KW, Won YJ, Kong HJ, Yim SH, Sung J, et al. National cancer incidence for the year 2002 in Korea. Cancer Res Treat. 2007;39:139-49.
14. Bonenkamp JJ, Hermans J, Sasako M, van de Velde CJ, Welvaart K, Songun I, et al. Extended lymph-node dissection for gastric cancer. N Engl J Med. 1999;340:908-14. (Pubitemid 29141051)
15. Hartgrink HH, van de Velde CJ, Putter H, Bonenkamp JJ, Klein Kranenbarg E, Songun I, et al. Extended lymph node dissection for gastric cancer: who may benefit? Final results of the randomized Dutch gastric cancer group trial. J Clin Oncol. 2004; 22:2069-77.
16. Park DJ, Lee HJ, Kim HH, Yang HK, Lee KU, Choe KJ. Predictors of operative morbidity and mortality in gastric cancer surgery. Br J Surg. 2005;92:1099-102. (Pubitemid 41284874)
17. Sasako M, Sano T, Yamamoto S, Kurokawa Y, Nashimoto A, Kurita A, et al. D2 lymphadenectomy alone or with para-aortic nodal dissection for gastric cancer. N Engl J Med. 2008;359: 453-62.
18. Kopp R, Rothbauer E, Ruge M, Arnholdt H, Spranger J, Muders M, et al. Clinical implications of the EGF receptor/ligand system for tumor progression and survival in gastrointestinal carcinomas: evidence for new therapeutic options. Recent Results Cancer Res. 2003;162:115-32.
19. Chong G, Cunningham D. Gastrointestinal cancer: recent developments in medical oncology. Eur J Surg Oncol. 2005;31: 453-60. (Pubitemid 40724083)
20. Garcia I, Vizoso F, Martin A, Sanz L, Abdel-Lah O, Raigoso P, et al. Clinical significance of the epidermal growth factor receptor and HER2 receptor in resectable gastric cancer. Ann Surg Oncol. 2003;10:234-41. (Pubitemid 40486955)
21. Gamboa-Dominguez A, Dominguez-Fonseca C, Quintanilla- Martinez L, Reyes-Gutierrez E, Green D, Angeles-Angeles A, et al. Epidermal growth factor receptor expression correlates with poor survival in gastric adenocarcinoma from Mexican patients: a multivariate analysis using a standardized immunohistochemical detection system. Mod Pathol. 2004;17:579-87. (Pubitemid 38868426)
22. Ito R, Nakayama H, Yoshida K, Matsumura S, Oda N, Yasui W. Expression of Cbl linking with the epidermal growth factor receptor system is associated with tumor progression and poor prognosis of human gastric carcinoma. Virchows Arch. 2004; 444:324-31. (Pubitemid 38553636)
23. Cascinu S, Labianca R, Barone C, Santoro A, Carnaghi C, Cassano A, et al. Adjuvant treatment of high-risk, radically resected gastric cancer patients with 5-fluorouracil, leucovorin, cisplatin, and epidoxorubicin in a randomized controlled trial. J Natl Cancer Inst. 2007;99:601-7. (Pubitemid 47073541)
24. Kim MA, Jung EJ, Lee HS, Lee HE, Jeon YK, Yang HK, et al. Evaluation of HER-2 gene status in gastric carcinoma using immunohistochemistry, fluorescence in situ hybridization, and real-time quantitative polymerase chain reaction. Hum Pathol. 2007;38:1386-93. (Pubitemid 47247482)
25. Yonemura Y, Ninomiya I, Yamaguchi A, Fushida S, Kimura H, Ohoyama S, et al. Evaluation of immunoreactivity for erbB-2 protein as a marker of poor short term prognosis in gastric cancer. Cancer Res. 1991;51:1034-8.
26. Galizia G, Lieto E, Orditura M, Castellano P, Mura AL, Imperatore V, et al. Epidermal growth factor receptor (EGFR) expression is associated with a worse prognosis in gastric cancer patients undergoing curative surgery. World J Surg. 2007;31: 1458-68. (Pubitemid 46945355)
27. Tanner M, Hollmen M, Junttila TT, Kapanen AI, Tommola S, Soini Y, et al. Amplification of HER-2 in gastric carcinoma: association with Topoisomerase IIalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. Ann Oncol. 2005;16:273-8. (Pubitemid 40309309)
28. Fujimoto-Ouchi K, Sekiguchi F, Yasuno H, Moriya Y, Mori K, Tanaka Y. Antitumor activity of trastuzumab in combination with chemotherapy in human gastric cancer xenograft models. Cancer Chemother Pharmacol. 2007;59:795-805. (Pubitemid 46440603)
29. Mathisen DJ, Kuo EY, Hahn C, Moncure AC, Wain JC, Grillo HC, et al. Inhaled nitric oxide for adult respiratory distress syndrome after pulmonary resection. Ann Thorac Surg. 1998;66: 1894-902. (Pubitemid 29087178)
30. Park YS, Hwang HS, Park HJ, Ryu MH, Chang HM, Yook JH, et al. Comprehensive analysis of HER2 expression and gene amplification in gastric cancers using immunohistochemistry and in situ hybridization: which scoring system should we use? Hum Pathol. 2012;43:413-22.
31. Ruschoff J, Nagelmeier I, Baretton G, Dietel M, Hofler H, Schildhaus HU, et al. Her2 testing in gastric cancer. What is different in comparison to breast cancer? Pathologe. 2010;31: 208-17.
32. Tsugawa K, Yonemura Y, Hirono Y, Fushida S, Kaji M, Miwa K, et al. Amplification of the c-met, c-erbB-2 and epidermal growth factor receptor gene in human gastric cancers: correlation to clinical features. Oncology. 1998;55:475-81. (Pubitemid 28396062)
33. Takita M, Onda M, Tokunaga A. Immunohistochemical demonstration of angiogenic growth factors and EGF receptor in hepatic metastases and primary human gastric cancer. Nihon Ika Daigaku Zasshi. 1998;65:358-66.
34. Nicholson RI, Gee JM, Harper ME. EGFR and cancer prognosis. Eur J Cancer. 2001;37(Suppl 4):S9-15.
35. Kim JS, Kim MA, Kim TM, Lee SH, Kim DW, Im SA, et al. Biomarker analysis in stage III-IV (M0) gastric cancer patients who received curative surgery followed by adjuvant 5-fluorouracil and cisplatin chemotherapy: epidermal growth factor receptor (EGFR) associated with favourable survival. Br J Cancer. 2009;100:732-8.
36. Halon A, Donizy P, Biecek P, Rudno-Rudzinska J, Kielan W, Matkowski R. HER-2 expression in immunohistochemistry has no prognostic significance in gastric cancer patients. Scientific- WorldJournal. 2012;2012:941259.
37. Janjigian YY, Werner D, Pauligk C, Steinmetz K, Kelsen DP, Jager E, et al. Prognosis of metastatic gastric and gastroesophageal junction cancer by HER2 status: a European and USA International collaborative analysis. Ann Oncol. 2012;23: 2656-62.
38. Greenman C, Stephens P, Smith R, Dalgliesh GL, Hunter C, Bignell G, et al. Patterns of somatic mutation in human cancer genomes. Nature. 2007;446:153-8. (Pubitemid 46398669)
39. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344:783-92. (Pubitemid 32222155)
40. Wagner AD, Moehler M. Development of targeted therapies in advanced gastric cancer: promising exploratory steps in a new era. Curr Opin Oncol. 2009;21:381-5.
41. Mendelsohn J, Baselga J. Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J Clin Oncol. 2003;21:2787-99. (Pubitemid 46606324)
42. Baselga J, Arteaga CL. Critical update and emerging trends in epidermal growth factor receptor targeting in cancer. J Clin Oncol. 2005;23:2445-59. (Pubitemid 47050835)
43. Hirono Y, Tsugawa K, Fushida S, Ninomiya I, Yonemura Y, Miyazaki I, et al. Amplification of epidermal growth factor receptor gene and its relationship to survival in human gastric cancer. Oncology. 1995;52:182-8.
44. Sanz-Ortega J, Steinberg SM, Moro E, Saez M, Lopez JA, Sierra E, et al. Comparative study of tumor angiogenesis and immunohistochemistry for p53, c-ErbB2, c-myc and EGFr as prognostic factors in gastric cancer. Histol Histopathol. 2000;15: 455-62. (Pubitemid 30218839)
45. Kameda T, Yasui W, Yoshida K, Tsujino T, Nakayama H, Ito M, et al. Expression of ERBB2 in human gastric carcinomas: relationship between p185ERBB2 expression and the gene amplification. Cancer Res. 1990;50:8002-9.
46. Hollywood DP, Hurst HC. A novel transcription factor, OB2-1, is required for overexpression of the proto-oncogene c-erbB-2 in mammary tumour lines. EMBO J. 1993;12:2369-75. (Pubitemid 23194187)
47. Chang HM, Jung KH, Kim TY, Kim WS, Yang HK, Lee KU, et al. A phase III randomized trial of 5-fluorouracil, doxorubicin, and mitomycin C versus 5-fluorouracil and mitomycin C versus 5-fluorouracil alone in curatively resected gastric cancer. Ann Oncol. 2002;13:1779-85. (Pubitemid 35439458)